Clinical trials: Enoxaparin, completed
Lymphoma, Thromboembolism
Heparin or Enoxaparin in Patients With Cancer
RATIONALE: Heparin or enoxaparin may be effective in preventing the formation of blood clots in patients with cancer who are undergoing surgery to remove the tumor.
- Conditions
- Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004875
- Testing
- enoxaparin, heparin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Venous Thromboembolism
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
Primary objective: To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd Secondary…
- Trial name
- NCT00077753
- Testing
- enoxaparin sodium
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 4,726 people
- Sponsor
- Sanofi
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Percutaneous Coronary Intervention
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of…
- Trial name
- NCT00077844
- Testing
- Enoxaparin sodium
- Volunteers
- 3,532 people
- Sponsor
- Sanofi
Acute Illness
Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin
The primary objective: To demonstrate in patients hospitalized for an acute medical illness that enoxaparin with Graduated Elastic Stockings is superior to enoxaparin-placebo with Graduated Elastic Stockings on overall mortality…
- Trial name
- LIFENOX (NCT00622648)
- Testing
- Enoxaparin
- Where
- 9 sites in Brazil, China and 7 more
- Volunteers
- 8,329 people
- Sponsor
- Sanofi
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total knee replacement surgery.
- Trial name
- NCT00917254
- Testing
- YM150, Enoxaparin
- Where
- 13 sites in Japan, Taiwan and 1 more
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
- Trial name
- NCT00913120
- Testing
- YM150, Enoxaparin
- Where
- 16 sites in Japan, South Korea and 2 more
- Volunteers
- 610 people
- Sponsor
- Astellas Pharma Inc
Abdominal Neoplasms
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
The primary objective of this study is to evaluate the effects of enoxaparin on venous thromboembolism incidence and bleeding rate (major and minor bleeding) in patients undergoing curative abdominal cancer surgery.
- Trial name
- NCT00723216
- Testing
- enoxaparin, Physical prophylaxis
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Sanofi
Acute Coronary Syndrome
Tirofiban and Enoxaparin in High Risk Coronary Intervention
Patients undergoing coronary angioplasty are frequently treated with new drugs that stop blood platelets working and so improve the success of the procedure. Individual patients may vary in the dose of the drug required.
- Trial name
- NCT00790387
- Testing
- Enoxaparin, Tirofiban, unfractionated heparin
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Prince Charles Hospital
Venous Thrombosis, Pulmonary Embolism
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
- Trial name
- NCT00097357
- Testing
- Apixaban, Enoxaparin, Warfarin
- Where
- 147 sites in United States, Argentina and 7 more
- Volunteers
- 1,238 people
- Sponsor
- Bristol-Myers Squibb
Venous Thrombosis
Enoxaparin in Acute Venous Thromboembolic Disease
Study objectives : To evaluate the efficacy/safety profile of enoxaparin once a day treatment in acute venous thromboembolic disease.
- Trial name
- NCT00265993
- Testing
- enoxaparin
- Where
- Turkey (Türkiye)
- Volunteers
- 251 people
- Sponsor
- Sanofi
Acute Coronary Syndrome
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)
The purpose of this study is to determine the efficacy and safety of enoxaparin compared to unfractionated heparin (UFH) for patients diagnosed with Acute Coronary Syndrome (ACS) in the emergency department (ED).
- Trial name
- NCT00077818
- Testing
- Enoxaparin sodium
- Sponsor
- Sanofi
Hip Fractures
Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery
The purpose of this study is to evaluate the effects of enoxaparin on bleeding and venous blood clots in patients with hip fracture surgery.
- Trial name
- NCT00685958
- Testing
- enoxaparin (XRP4563)
- Where
- Japan
- Volunteers
- 54 people
- Sponsor
- Sanofi
Inflammation
Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery
The purpose of this study is to determine if intraocular infusion of low-molecular weight heparin (enoxaparin) influences postoperative inflammation following pediatric cataract surgery with intraocular lens (IOL) implantation.
- Trial name
- NCT00986076
- Testing
- Enoxaparin, Balanced Salt Solution
- Where
- India
- Volunteers
- 23 people
- Sponsor
- Iladevi Cataract and IOL Research Center
Cancer
Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients
In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated…
- Trial name
- NCT00375076
- Testing
- enoxaparin
- Where
- Austria
- Sponsor
- Medical University of Vienna
Submassive Pulmonary Embolism
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study
An exploratory, multicenter, randomized, placebo-controlled, double blind, dose escalation study comparing a standard therapy for submassive pulmonary embolism (Enoxaparin sodium) to a combined therapy of Drotrecogin alfa…
- Trial name
- NCT00191724
- Testing
- Drotrecogin Alfa (Activated), Enoxaparin
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Venous Thromboembolism
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE. The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but heparins have to be applied by…
- Trial name
- ODIXa-HIP2 (NCT00398905)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 61 sites in Austria, Belgium and 11 more
- Volunteers
- 726 people
- Sponsor
- Bayer
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi
Arthroplasty, Replacement, Hip
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
This study is performed to confirm the optimal dose for THR (total hip replacement).
- Trial name
- NCT00349180
- Testing
- Enoxaparin sodium
- Where
- Japan
- Volunteers
- 156 people
- Sponsor
- Sanofi
Bruises
Patients Preference With Self-Injection: The PRISM Study
The purpose of this study is to determine which short-acting blood thinner (low-molecular-weight heparin [Enoxaparin] or unfractionated heparin) is associated with less discomfort and bruising when given as a subcutaneous (under…
- Trial name
- NCT00253396
- Testing
- Unfractionated heparin, Enoxaparin
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation